Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 9
Submit an article Journal homepage
832
Views
10
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

Safety of vedolizumab in the treatment of Crohn’s disease and ulcerative colitis

Matilda HaganUniversity of Maryland, Division of Gastroenterology and Hepatology, Department of Medicine, 100 North Greene Street, Lower Level, Baltimore, MD 21201, [email protected];Institute for Digestive Health and Liver Disease, Mercy Medical Center, Baltimore, MD, USA
, MD &
Raymond K CrossUniversity of Maryland, Division of Gastroenterology and Hepatology, Department of Medicine, 100 North Greene Street, Lower Level, Baltimore, MD 21201, [email protected]
, MD MS
Pages 1473-1479 | Published online: 03 Jul 2015

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Gregor Novak, Pieter Hindryckx, Reena Khanna, Vipul Jairath & Brian G. Feagan. (2017) The safety of vedolizumab for the treatment of ulcerative colitis. Expert Opinion on Drug Safety 16:4, pages 501-507.
Read now
Andreas Stallmach, Carsten Schmidt & Niels Teich. (2016) Vedolizumab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 10:2, pages 165-175.
Read now

Articles from other publishers (8)

Huai-Yu Yang, Dan Wang, Cui Chen, Yu Liu, Chao Han, Ye Gao, Zhao-Shen Li, Zhuan Liao & Liang-Hao Hu. (2021) Global research status of gastroenterology and hepatology. Medicine 100:15, pages e25291.
Crossref
Hye Jin Lee, Emily B. Ehlerding & Weibo Cai. (2018) Antibody‐Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases. ChemBioChem 20:4, pages 422-436.
Crossref
Lydia C T Buer, Marte L Høivik, David J Warren, Asle W Medhus & Bjørn A Moum. (2018) Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflammatory Bowel Diseases 24:5, pages 997-1004.
Crossref
Koji Matsuhisa, Akihiro Watari, Kazuki Iwamoto, Masuo Kondoh & Kiyohito Yagi. (2017) Lignosulfonic acid attenuates NF-κB activation and intestinal epithelial barrier dysfunction induced by TNF-α/IFN-γ in Caco-2 cells. Journal of Natural Medicines 72:2, pages 448-455.
Crossref
Elaine M. Conner, John Reglinski, W. Ewen Smith & I. Jack Zeitlin. (2017) Schiff base complexes of copper and zinc as potential anti-colitic compounds. BioMetals 30:3, pages 423-439.
Crossref
Uri Kopylov, Yulia Ron, Irit Avni-Biron, Benjamin Koslowsky, Matti Waterman, Saleh Daher, Bella Ungar, Henit Yanai, Nitsan Maharshak, Ofer Ben-Bassat, Lev Lichtenstein, Ariella Bar-Gil Shitrit, Eran Israeli, Doron Schwartz, Eran Zittan, Rami Eliakim, Yehuda Chowers, Shomron Ben-Horin & Iris Dotan. (2017) Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease?the Israeli Real-World Experience. Inflammatory Bowel Diseases 23:3, pages 404-408.
Crossref
Alexander A. Navarini, Petr Hruz, Christoph T. Berger, Tie Zheng Hou, Charlotte Schwab, Annemarie Gabrysch, Rebecca Higgins, Natalie Frede, Barbara-Christina Padberg Sgier, Olle K?mpe, Anne-Val?rie Burgener, Florian Marquardsen, Fabian Baldin, Marc Bigler, Anne Kistner, Annaise Jauch, Olivier Bignucolo, Benedikt Meyer, Fabian Meienberg, Matthias Mehling, Lukas T. Jeker, Ingmar Heijnen, Thomas D. Daikeler, Jan-Olaf Gebbers, Bodo Grimbacher, David M. Sansom, Raphael Jeker, Christoph Hess & Mike Recher. (2017) Vedolizumab as a successful treatment of CTLA-4?associated autoimmune enterocolitis. Journal of Allergy and Clinical Immunology 139:3, pages 1043-1046.e5.
Crossref
Emily E. Vivio, Navya Kanuri, Joanna J. Gilbertsen, Kelly Monroe, Neelendu Dey, Chien-Huan Chen, Alexandra M. Gutierrez & Matthew A. Ciorba. (2016) Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. Journal of Crohn's and Colitis 10:4, pages 402-409.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.